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The term variant angina, first used by Prinzmetal et al. (1)
in 1959, denotes chest discomfort with classic features of
angina but occurring at rest or at night (usually the early
morning hours) rather than with exertional or emotional
stress. The pain is often associated with ST segment
elevation and is relieved by nitroglycerin. A female predom-
inance and frequent association with cigarette smoking, as
well as migraine syndromes and Raynaud’s phenomenon,
have been recognized. In 1973, spontaneous coronary spasm
was documented during coronary angiography in a patient
with variant angina (2), confirming the mechanism origi-
nally proposed by Prinzmetal et al. (1). Coronary spasm
superimposed on minimal-to-mild atherosclerosis is the
generally accepted proximate cause of variant angina, but
definitive mechanisms have remained elusive. Although
chest pain syndromes atypical for angina in the absence of
important atherosclerotic obstructions are common, variant
angina as described by Prinzmetal et al. (recurrent chest pain
at rest with ST elevation) is less common but not rare. The
diagnosis is challenging and requires observation of spasm
associated with the patient’s typical symptoms and electro-
cardiographic (ECG) changes. Coronary spasm may of
course contribute to other ischemic coronary syndromes,
including variable threshhold exertional angina.
Ergonovine, an ergot alkaloid used to control postpartum
uterine bleeding, was found in 1949 to provoke angina, and
was proposed in 1963 as a diagnostic test for coronary
disease (3). In early studies, however, patients received very
high doses of ergonovine. Severe angina was not uncommon
and a reported death in a small series caused the test to be
abandoned. Ergonovine testing with very low doses in the
catheterization laboratory was utilized frequently in the late
1970s and early 1980s to help identify the mechanism of
chest pain when only “insignificant” coronary artery disease
(CAD) was found by angiography. Protocols directed cau-
tious administration of increasing doses of intravenous (IV)
or intracoronary ergonovine, with angiography several min-
utes after each dose or whenever chest pain or ECG changes
were noted. Ergonovine, which has structural homology to
norepinephrine, causes contraction of vascular smooth mus-
cle mediated at least in part by serotonin receptors and
stimulates endothelial nitric oxide generation (4). The usual
result is mild generalized vasoconstriction (,20% diameter
narrowing) in apparently normal coronary arteries (3,5).
Strict criteria have been used to define a positive ergonovine
angiographic study: near total, and localized spasm, repro-
ducing the patient’s typical symptoms or associated ST
segment shifts. Using these criteria, positive ergonovine
studies have been reported in 20% to 40% of patients with
clinically suspected variant angina (6). The test was gener-
ally believed to be low risk, although cases of intractable
spasm requiring intracoronary nitroglycerin have been re-
ported (7,8). When ergonovine was used in .1,000 con-
secutive patients by Bertrand et al. (6), there were also four
cases of ventricular fibrillation with successful resuscitation.
Two forms of ergonovine (ergonovine maleate and methy-
lergonovine) have been used in the angiographic laboratory
with very similar, if not identical, responses. Only methyl-
ergonovine is currently available in the U.S.
In this issue of the Journal, Song et al. (9) follow up on
their earlier proposal for a noninvasive test for coronary
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spasm, using ergonovine outside of the catheterization
laboratory with continuous monitoring of wall motion by
echo. This report appears in an era when variant angina is
rarely identified clinically and when ergonovine testing in
the invasive laboratory is unusual. For example, two decades
ago, in our institution, we were seeing two to three new
cases of variant angina per month; now we see less than two
per year. The reason for this marked change in frequency is
not clear. The widespread use of calcium antagonists, which
are highly effective in preventing coronary spasm, is one
possibility. Lack of testing is another. For example, in one of
our hospitals, 1,240 non–transplant-related diagnostic cor-
onary arteriograms were performed in 1999, but only 6
ergonovine studies were performed! Two decades ago, we
were doing about six ergonovine studies per week. In this
context, the provocative report on ergonovine echocardiog-
raphy raises a number of issues, including safety, specificity
and usefulness in clinical practice.
Safety. Song and colleagues performed .1,500 ergonovine
studies, most in an outpatient setting, over seven years
without serious complications. This is certainly one of the
largest reported series of ergonovine studies available in the
literature. They used small incremental doses of ergonovine,
0.05 mg IV every 5 min, to a total maximal dose of 0.35 mg
or until side effects or a positive end point (wall motion
abnormality) necessitated termination. Some invasive pro-
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tocols have used ergonovine doses of 0.05 mg, 0.15 mg and
0.25 mg at 3-min intervals (3), whereas others limited the
total dose to 0.2 mg (5). The authors propose that the
ergonovine test with echo monitoring may be safer than the
ergonovine with angiography because continuous observa-
tion of wall motion will allow earlier termination of the
study, before onset of severe ischemia (manifest as chest
pain and ST elevation). Continuous monitoring of the
coronary angiogram is not possible. Although large, this is
the experience of a single center, and safety will need to be
confirmed at other centers with a wider variety of cases and
in the hands of different operators before the test can be
recommended in general practice. Apparently, the ergono-
vine echo is interpreted just as any other stress echo,
implying that skill in stress echo would be adequate for
interpretation of the ergonovine stress. This will need to be
confirmed. The authors also mention that ST elevation
occurred in 10 patients with poor echocardiographic win-
dows. Coronary spasm, the initiating event, may be visual-
ized early by angiography. Based on animal research, the
authors suggest that the spasm-induced ischemia will pro-
duce a localized decrease in contractility (visualized by echo)
before the onset of ECG changes of severe ischemia. If the
continuous monitoring of wall motion contributes to the
safety of this procedure, one cannot condone performing an
ergonovine echo study in any patient with poor windows, as
the safety is unknown and diagnostic capability is limited.
Thus, the risk-benefit ratio in each patient must be also
considered. We are willing to recommend procedures with
significant risk to diagnose and treat critical CAD. How-
ever, we should demand a very low risk procedure to identify
coronary spasm superimposed on no or only mild CAD, as
these patients have been shown in both white and Japanese
populations to have a relatively good outcome during
follow-up.
Specificity. To determine the specificity of a test, one must
have some reasonable reference standard. Song et al. (9)
compare the results of noninvasive ergonovine echo with the
results of invasive ergonovine testing. The specificity of
ergonovine in conjunction with coronary angiography was
addressed by Bertrand et al. (6) in 1982. When ergonovine
was given in .1,000 consecutive patients undergoing cath-
eterization, the frequency of positive ergonovine provoca-
tion was as follows: 1.2% in patients with chest pain atypical
for angina pectoris and normal/near normal arteries; 4.3% in
patients with effort angina only; 13.8% in patients with
effort plus rest angina; 38% in patients with rest angina only
(203 patients); and 0% in patients with cardiomyopathy.
Overall, 59% of spasm episodes occurred on fixed lesions in
this study (6). These data allow us to conclude that patients
with rest angina only are much more likely to have a positive
ergonovine study than patients with either chest pain
atypical for angina or effort angina only. Also, the data on
the sensitivity of ergonovine testing with angiography are
limited as there is no reference standard except observation
of spontaneous spasm. We cannot conclude that a negative
ergonovine study excludes spasm with 100% certainty as a
mechanism of chest pain. In the institution where Song and
colleagues practice, 200 to .300 evaluations for possible
coronary spasm were ordered each year. Overall, 32% of the
ergonovine echos in their center were positive, with 44%
positive tests in patients suspected of having variant angina.
For most of their patients, the only screening for significant
fixed atherosclerotic obstructive disease was an exercise
stress test with only ECG monitoring, which has a sensi-
tivity of only 75% to 80% for detecting significant CAD.
Perhaps fewer ergonovine studies would have been neces-
sary if a more sensitive screening test for fixed CAD had
been used. One must be concerned that ergonovine testing
would be associated with higher risk for complications in
patients with more severe CAD. In the selected subset of
patients who underwent angiography, the authors found
agreement (both studies positive or both negative for pro-
voked ischemia) in 202 of 218 patients (93%), suggesting
equivalent diagnostic accuracy. Of note also, 152 of 218
patients had a positive ergonovine angiographic test (70%).
This is a much higher positive rate than the overall
population, confirming that this is a highly selected group,
perhaps a group selected for angiography due to the positive
ergonovine echo. One cannot extrapolate the accuracy of the
test in this highly selected group to the overall population in
which it was ordered or to some other population in which
it may be utilized in the future. It would be interesting to
know the severity of fixed coronary disease found in these
patients who were selected for angiography, and whether
the ischemic territory identified by the two tests was the
same. We and others have described cases with spasm
occurring in multiple coronary arteries. This may be more
difficult to recognize by echo monitoring. In the initial
description by Song et al. (10) in 1996, in which the sites of
spasm identified by echo and angiography were compared,
the echo failed to identify cases of multivessel spasm. This
may occur if the ergonovine-echo study is terminated as
soon as any wall motion abnormality is identified and may
not be an important clinical limitation.
In summary, it would seem prudent to perform a more
sensitive screen for significant fixed coronary disease prior to
any noninvasive ergonovine-echo study, to avoid subjecting
a patient with a severe coronary lesion to provoked spasm in
an outpatient setting without the ability to promptly reverse
spasm with intracoronary nitroglycerin. Patients with posi-
tive ergonovine tests will still be a mixed group, with most
having minimal-to-moderate fixed disease and some pa-
tients having severe disease missed by initial screening test.
We must also ask ourselves whether a positive ergonovine-
echo suggesting spasm would be enough for patient man-
agement, or would we still need a better characterization of
the severity of fixed disease with angiography?
Usefulness. Finally, we must ask ourselves how we will use
this noninvasive ergonovine-echo test in clinical practice in
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an era when we rarely bother to use ergonovine in the
catheterization laboratory. In the most recent American
College of Cardiology/American Heart Association Coro-
nary Angiography Guidelines, expert consensus supported
the usefulness of provocative testing for coronary spasm in
patients with “recurrent episodes of apparently ischemic
cardiac pain at rest” and “normal or mildly abnormal
coronary angiogram” but no clinical observations to sub-
stantiate the diagnosis of variant angina (11). Song and
colleagues report a steady decline in the use of ergonovine
during angiography at their institution in Korea, accompa-
nied by an increase in the use of ergonovine-echo. There has
been a similar marked decline in the use of ergonovine in
the catheterization laboratories in U.S. institutions, even
without the availability of a noninvasive test to take its place.
We must ask ourselves why we have abandoned the use of
ergonovine and what has happened to the patients with
coronary spasm who we worked so hard to identify in the
late 1970s and early 1980s. Perhaps cardiologists are now
only interested in patients in need of angioplasty or stenting
and do not want to be bothered with milder forms of
ischemic heart disease. Some may consider the test too
time-consuming to be performed in the busy invasive-
interventional laboratory. Perhaps some are still concerned
about the safety of ergonovine, even in the catheterization
laboratory, where a serious complication, although rare, is
not acceptable in a disease with a relatively good prognosis.
Perhaps we see variant angina less often because of the
widespread use of calcium antagonists for chest pain and/or
hypertension. Maybe cardiologists have found that an em-
piric trial of calcium antagonists, perhaps combined with
nitrates, is as helpful as an ergonovine test used to be in the
evaluation of possible spasm. We suspect that many cardi-
ologists became disillusioned with the indiscriminate use of
ergonovine in patients with chest pain syndromes atypical
for transient ischemia. What should they do with the
positive results that sometimes occurred in these patients?
Did they lose confidence in a test that was perhaps overused
and maybe even inappropriately used? In this setting, did
they stop considering the diagnosis of variant angina and
abandon any attempt to confirm the diagnosis and perhaps
manage symptoms more appropriately? The report of Song
and colleagues challenges all of us to look more carefully for
patients with variant angina and consider whether a renais-
sance in provocative testing for coronary spasm is needed.
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